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ABSTRACT 
Motoneuron diseases, like spinal bulbar muscular atrophy (SBMA) and amyotrophic lateral 
sclerosis (ALS), are associated with proteins that because of gene mutation or peculiar structures, 
acquire aberrant (misfolded) conformations toxic to cells. To prevent misfolded protein toxicity, 
cells activate a protein quality control (PQC) system composed of chaperones and degradative 
pathways (proteasome and autophagy). Inefficient activation of the PQC system results in 
misfolded protein accumulation that ultimately leads to neuronal cell death, while efficient 
macroautophagy/autophagy-mediated degradation of aggregating proteins is beneficial. The latter 
relies on an active retrograde transport, mediated by dynein and specific chaperones, such as the 
HSPB8-BAG3-HSPA8 complex. Here, using cellular models expressing aggregate-prone proteins 
involved in SBMA and ALS, we demonstrate that inhibition of dynein-mediated retrograde 
transport, which impairs the targeting to autophagy of misfolded species, does not increase their 
aggregation. Rather, dynein inhibition correlates with a reduced accumulation and an increased 
clearance of mutant ARpolyQ, SOD1, truncated TARDBP/TDP-43 and expanded polyGP 
C9ORF72 products. The enhanced misfolded proteins clearance is mediated by the proteasome, 
rather than by autophagy and correlates with the upregulation of the HSPA8 cochaperone BAG1. In 
line, overexpression of BAG1 increases the proteasome-mediated clearance of these misfolded 
proteins. Our data suggest that when the misfolded proteins cannot be efficiently transported 
towards the perinuclear region of the cells, where they are either degraded by autophagy or stored 
into the aggresome, the cells activate a compensatory mechanism that relies on the induction of 
BAG1 to target the HSPA8-bound cargo to the proteasome in a dynein-independent manner.  
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INTRODUCTION 
Motoneuron diseases (MNDs) are neurodegenerative diseases (NDs) in which cortical and spinal 
motoneurons are primarily affected, although also other cell types (e.g., glial or muscle cells) 
contribute to onset and/or progression of disease.1-11 Some MNDs forms are associated with the 
presence of toxic proteins with aberrant conformations (misfolded proteins).12-15 Typical examples 
of MNDs associated with misfolded proteins toxicity are spinal and bulbar muscular atrophy 
(SBMA) and amyotrophic lateral sclerosis (ALS). SBMA is due to an expansion of the CAG repeat 
in exon 1 of the androgen receptor (AR) gene translated into an abnormally long polyQ tract in the 
AR (androgen receptor) protein (ARpolyQ).16 Interestingly, elongated polyQ exerts neurotoxicity 
only after ARpolyQ activation by its natural ligand testosterone (T),17 which implies chaperones 
release and protein conformational changes for nuclear translocation.18 Protein misfolding is also 
relevant in ALS either in sporadic (sALS) or familial (fALS) forms, which are clinically 
indistinguishable. While fALSs represent only 10% of total ALSs, several fALS-responsible mutant 
proteins (e.g., SOD1 [superoxide dismutase 1, soluble], TARDBP/TDP-43 [TAR DNA binding 
protein], FUS, OPTN [optineurin], UBQLN [ubiquilin], etc.) have been found to aberrantly behave 
as wild-type (WT) forms also in most sALS,19 suggesting that common pathogenic mechanisms 
contribute to both fALS and sALS.  
 To prevent misfolded protein toxicity, cells respond by enhancing the functions of the 
protein quality control (PQC) system. The PQC system comprises chaperone proteins (e.g., the heat 
shock proteins, HSPs) and degradative systems (e.g., the ubiquitin proteasome system, UPS; the 
different autophagic pathways, etc.). When poorly removed by the PQC system, misfolded proteins 
accumulate in cells forming different types of inclusions. Large cytoplasmic inclusions are 
generally thought to be protective, at least in their initial stages of formation,18,20-23 Inclusions also 
localize into the nucleus or even in neurites exerting toxicity by altering several pathways 
regulating neuronal functions.24,25 Inclusion formation proceeds through several steps. The process 
typically begins with the dynein and dynactin mediated transport of misfolded proteins escaping 
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proteasomal degradation to the microtubule-organizing center (MTOC), where they form 
aggresomes.26 Aggresomes could be removed by autophagy, but, when this system fails, 
aggresomes are gradually converted into insoluble inclusions.  
 Several multiprotein complexes assist the misfolded proteins transport to the MTOC. One 
example is a complex involving the HSPB8 (heat shock protein 8) chaperone, a small HSP family 
member. HSPB8 promotes autophagic removal of misfolded proteins, including ARpolyQ, HTT 
(huntingtin)-polyQ, ATXN3 (ataxin 3)-polyQ, mutant SOD1, full-length TARDBP (FL-TARDBP) 
and its ALS-associated fragments, in different ND models.27-33 HSPB8 acts together with BAG3 
(BCL2-associated athanogene 3), a cochaperone of HSPA8/HSC70 (heat shock protein 8) and 
HSPA1A.28,29,34-37 All these proteins are induced when the proteasome is inhibited27-29 to route 
misfolded proteins to autophagy.36,38 The ubiquitin ligase STUB1/CHIP (STIP1 homology and U-
box containing protein 1) assists this complex by ubiquitinating clients28,29,39 for their SQSTM1/p62 
(sequestosome 1)-mediated targeting to phagophores, the precursors to autophagosomes.40 BAG3 is 
a scaffold protein that plays a central role in autophagy.41-45 With its proline-rich (PXXP) repeat 
motif it specifically bridges misfolded proteins to the dynein complex via the YWHA/14-3-3 
protein, to allow their delivery to the MTOC for their autophagic degradation.28,29,39,42 Several 
misfolded proteins found in aggresomes are not ubiquitinated,46 and BAG3 activity can also be 
independent from their ubiquitination status.42 Alternatively, aggresome formation is controlled by 
HDAC6 (histone deacetylase 6), which requires substrate ubiquitination; also HDAC6 interacts 
with dynein (through DCTN1/p150Glued [dynactin 1]), but only after ubiquitination of substrates 
escaping UPS degradation,47-51 and transports misfolded protein to MTOC.47,49,52-54 Both BAG3-
mediated and HDAC6-mediated clients routing to aggresomes require dynein.26  
 Notably, mutations in DYNC1H1, the gene coding for dynein (dynein cytoplasmic 1 heavy 
chain 1, the essential subunit of the cytoplasmic dynein complex) are linked to different neuronal 
diseases55-62 involving autophagy alterations. Therefore, dynein impairment may have a role in 
neurodegeneration. Surprisingly, dynein activity deficiency correlates to improvement of motor 
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function and prolonged survival of the transgenic SOD1G93A fALS mice 63-65 suggesting that the 
involvement of dynein in disease progression may be more compex than expected.  
 In this study, we analyzed the role of dynein on the clearance of misfolded ARpolyQ and of 
different proteins involved in ALS (human mutant SOD1, TARDBP, RAN translated polyGP from 
C9ORF72). We found that depletion or chemical inhibition of dynein decreased the aggregation of 
misfolded proteins and enhanced their proteasomal degradation. Dynein inhibition was paralleled 
by an upregulation of BAG1 (BCL2-associated athanogene 1) expression, which targets the HSPA8 
and HSPA1A-bound clients to the UPS.38,66,67 Indeed, BAG1 overexpression enhanced misfolded 
protein degradation via the proteasome pathway even when dynein was inhibited. If BAG3 dynein-
mediated transport of misfolded species to autophagy fails, an alternative pathway, which relies on 
BAG1 and the UPS, is activated to efficiently assist misfolded protein clearance. We postulate that 
the alteration of the rerouting system from autophagy to proteasome (and possibly vice versa) when 
one of the 2 degradative pathways is overwhelmed or impaired, rather than the alteration of the 
degradative pathway per se might be responsible for the accumulation of aggregate-prone proteins 
in MNDs. 
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RESULTS  
 
HSPB8 promotes the clearance of misfolded ARpolyQ 
We initially validated the prodegradative effect of HSPB8 on aggregated forms of ARpolyQ 
generated by T treatment. Fig. 1A shows that mutant ARpolyQ resides in the cytoplasm in basal 
conditions and translocates to the nucleus after T treatment. In approximately one third of total 
transfected cells20,68 (see also Fig. 4F) nuclear translocation was incomplete and the misfolded 
ARpolyQ fraction aggregated as inclusions visible by immunofluorescence analysis (IF; Fig. 1A), 
and quantifiable in Filter Retardation Assay (FRA; Fig. 1B; compare lane 1 and lane 2, without or 
with T, respectively) in agreement with previous reports.31,32,69 In basal conditions (T-untreated 
cells) ARpolyQ aggregation propensity is barely detectable and comparable to that of wild-type 
(WT) AR (see below and FRA in Fig. S1). The levels of insoluble WT AR (AR.Q23 in the absence 
or presence of T) and of T-untreated ARpolyQ (AR.Q46) were much lower than that found for T-
activated ARpolyQ (Fig. S1, almost 2-fold increase over its control, untreated AR.Q46). We have 
already shown that the misfolded ARpolyQ accumulates upon T treatment, decreasing autophagy 
and leaving unaffected the proteasome,31,32,69 and have found that the chaperone HSPB8 favors its 
degradation by autophagy. In line, here we show that both the T-induced cytoplasmic inclusions 
(Fig. 1A) and the insoluble ARpolyQ fraction (Fig. 1B, upper inset and quantification in bar graphs) 
disappear when HSPB8 is overexpressed, and the effect was present, at a lower intensity, on the 
total soluble ARpolyQ protein identified by western blot (WB; Fig. 1B lower inset, quantification in 
Fig. S2).  No major effects are exterted by HSPB8 on WT AR.32 Since HSPB8 requires BAG3 
30,34,70, for SQSTM1 cargo insertion into phagophores at the MTOC,28,29,39 and BAG3 utilizes the 
dynein (and the YWHA/14-3-3 protein which cosegregates with ALS-protein aggregates71-74)-
mediated transport of the complex, we analyzed the role of dynein in HSPB8-mediated autophagic 
clearance of aggregates.  
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 We designed a specific siRNA recognizing Dync1h1 (Dync1h1 siRNA) that abolished 
dynein production in NSC34 cells (Fig. 1C and Fig. 1D), and then we evaluated its effects on GFP-
tagged ARpolyQ (GFP-AR.Q39) stably expressed in NSC34 cells in an inducible manner under the 
TetON promoter. Unexpectedly, after dynein downregulation, we found a significant reduction of 
the total amount of T-induced misfolded ARpolyQ insoluble species retained by the cellulose 
acetate membrane in FRA (Fig. 1E). In addition, a significant decrease of the total levels of ARs in 
WB was observed in dynein donwregulated samples, both in the case of unactivated ARpolyQ 
(normally processed by the proteasome) and of T-treated ARpolyQ (see WB quantification in Fig. 
S2). 
 
Effects of dynein impairment on autophagy in basal conditions or after autophagy activation. 
We next investigated whether dynein depletion correlated with a compensatory activation of 
autophagy. We initially evaluted the effects of dynein impairment in basal autophagy conditions in 
NSC34 cells. We measured the intracellular distribution and levels of the 2 autophagy markers 
SQSTM1 and MAP1LC3/LC3 (microtubule-associated protein 1 light chain 3). To our surprise, we 
found that in basal conditions, dynein downregulation does not alter the overall properties of these 
markers (Fig. 2A), suggesting that its impact on cargo delivery does not results in a compensatory 
activation of autophagy. However, since dynein may also regulate the fusion between the 
autophagosomes and lysosomes, we then further investigated the involvement of dynein on LC3 
dynamics. To this purpose, we pharmacologically blocked the basal autophagic flux with NH4Cl, 
and we found that the levels of the lipidated LC3-II form were similarly significantly increased by 
this treatment in all conditions tested (see quantification of LC3-II to TUBA and LC3-II to LC3-I 
ratio in Fig. 2B and Fig. S2, respectively). The relatively low LC3-II accumulation in the presence 
of NH4Cl and almost constant levels of LC3-I (compare basal vs activated autophagy in Fig. 3D) 
are supportive of low levels of basal autophagic activity in these cells. Overall, these results support 
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preservation of basal autophagic flux even upon dynein knockdown and suggest that dynein has 
only a minor effect on the basal autophagic flux.  
 However, it is possible that, whereas Dync1h1 siRNA is very efficient in each single cell, 
some cells may resist to transfection and dynein downregulation may not involve the whole cell 
population. Moreover, ATP-independent activities of dynein have been described,75 with possible 
impact on different intracellular pathways. This promped us to adopt a second approach to block 
dynein-mediated transport. Therefore, we chemically and selectively blocked the ATP-dependent 
activity of dynein (specifically required for cargo delivery) with erythro-9-[3-2-(hydrosynonyl)] 
adenine (EHNA).76,77 EHNA binds specifically to the ATP binding site of dynein inhibiting the 
ATPase and motor activities, selectively impairing the microtubule-based transport toward the 
MTOC. We initially compared the effects of EHNA with that of dynein-silencing in our NSC34 
cells, by analyzing LC3-II levels in the presence or absence of NH4Cl to block its lysosomal 
degradation (Fig. 2C and Fig. S2). 
 We found that the effects of dynein downregulation and of EHNA on the LC3 turnover and 
LC3-II to LC3-I ratio overlap in both conditions, supporting the view that dynein impairment has 
no effect on LC3 turnover in condition of basal autophagy (Fig. 2C and Fig S3). At present, we are 
unable to explain why and how autophagosomes assemble when autophagy is running at basal 
levels, and the relevance of dynein in this context. One possibility is that, even after siRNA or 
EHNA treatment, cells maintain a residual dynein activity, which may be sufficient to substain the 
autophagosome formation at low levels, or other alternative dynein-independent pathways of cargo 
delivery may exist. It is also possible that in condition of basal autophagy, the fusion between 
autophagosomes and lysosomes (which is required to degrade LC3-II into the autolysosomes) is 
only partially substained by dynein; the role of dynein may become more relevant when the flux is 
activated in response to specific stimuli. However, since misfolded proteins likely activate 
autophagy (and may also block autophagy),32 we analyzed the effects of dynein impairment when 
autophagy flux was pharmacologically induced. To this purpose, we compared the alteration 
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induced by EHNA on autophagy in basal conditions or induced with trehalose (an MTOR-
independent autophagy activator31,32,78-80). First, EHNA alone had no effect on SQSTM1 or on LC3 
mRNA expression levels (Fig. 3A and 3B, respectively). Trehalose induced the expression of 
SQSTM1 and LC3 mRNAs; but, dynein inhibition with EHNA counteracted the effects of trehalose 
on the expression of the 2 autophagy markers (Fig. 3A and 3B). This suggests that cells respond to 
dynein inhibition with a downregulation of autophagy activation (and/or possibly by activating 
alternative pathways? see later). The data were confirmed also with both IF (Fig. 3C) and WB (Fig. 
3D and quantification in Fig. S3) analyses. Trehalose-treated cells were highly immunoreactive (Fig. 
3C, upper panels); to appreciate the effets of EHNA treatment (Fig. 3C, lower panels) images at a 
lower gain were captured (low sensitivity: L.S.). Indeed, trehalose increased endogenous SQSTM1 
and LC3 protein levels (IF quantification per cells reported in bar graph of Fig. 3C, upper panels, 
and WB analysis in Fig. 3D, with relative quantification in the bar graphs and in Fig. S3) and 
induced the classical distribution expected for the 2 markers when autophagy is activated (i.e., LC3-
II punctated distribution) (Fig. 3C). In basal conditions, EHNA does not modify the endogenous 
LC3 levels (Fig. 3C, see also Fig. 2C) or its conversion to LC3-II (Fig. 3C and 3D, and 
quantification in the lower bar graph and Fig. S3), while it significantly increased of almost 2-fold 
SQSTM1 immunoreactive levels in IF (Fig. 3C, left panels), and 1.7 fold in WB (Fig. 3D and S4). 
A difference has been found between the effects of dynein inhibition with ENHA and dynein 
downregulation with Dync1h1 siRNA on SQSTM1 immunoreactivity quantify using confocal 
microscopy (compare Fig. 2A with Fig. 3C). However, as a small molecule, EHNA affects the 
entire pool of cells, while the siRNA only targets a fraction of them. Therefore, although both 
experimental approaches affect autophagy, differences can be observed in the 2 conditions. It is also 
possible that these differences are associated with the ATP-independent activities of dynein (see 
above and ref. 75).  
 During trehalose-stimulated autophagy, we found that EHNA reduced the overall levels of 
the endogenous SQSTM1 and LC3 proteins (IF in Fig. 3C), in agreement with the observed 
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transcriptional downregulation (Fig. 3A and Fig. 3B). Moreover, analysis of LC3-II degradation by 
addition of NH4Cl, in cells with trehalose-stimulated autophagy (Fig. 3D and quantification in the 
lower bar graph and in Fig. S3), revealed that EHNA abolished the increase in LC3-II turnover 
induced by trehalose. These data suggest that dynein inhibition counteracts the formation of 
trehalose-induced LC3-II-positive autophagosomes, possibly by preventing their formation. 
Therefore, dynein inhibition with EHNA does not affect autophagy in basal conditions, but prevents 
the trehalose-stimulated formation of autophagosomes and this may in turn stimulate the activation 
of alternative pathways of degradation. 
 
Dynein blockage reduces the ARpolyQ aggregation in an autophagy-independent manner 
To test the role of dynein on ARpolyQ clearance we utilized different and complementary cell 
models of SBMA, based on neuronal cells stably expressing in an inducible manner or transiently 
expressing WT or mutant ARpolyQ. Based on data from literature of different laboratories, 
including ours,20,25,31,32,69,81-87 as control for ARpolyQ we utilized either the WT AR (with 
unexpanded polyQ) or the unactivated (unbound) ARpolyQ (which is not pathogenic). When the 
experimental design was particularly complex, we compared the "neurotoxic" ligand activated 
ARpolyQ, with the "not neurotoxic" unactivated (nonpathogenic) ARpolyQ.18,20,25,32,69,86-88 
 We initially used rat pheochromocytoma PC12 cells stably expressing AR.Qn (n=112, and 
WT n=10, developed and kindly provided to us by Dr. Diane Merry, Thomas Jefferson University, 
Philadelphia, PA, USA89) with a very long polyQ tract highly prone to aggregate into the 
nucleus.31,90 Using these models, in FRA (Fig. 4A), we found that T-induced misfolded AR.Q112 
insoluble species formation, while EHNA reduced this accumulation (Fig. 4A). EHNA had no 
effects on T-untreated AR.Q112 or on WT AR (AR.Q10), which do not form insoluble inclusions 
(Fig. 4A). We then used mouse motoneuronal NSC34 cells stably expressing GFP-AR.Qn (n=39 
and control n=0), where the mutant polyQ has a size that causes SBMA, but with late onset and low 
progression rate, and it is in the very low range of expansions identified in patients.91-93 AR.Q39 
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does not form intracellular inclusions visible in IF (not shown), but it forms low amount of 
insoluble species detectable in FRA (Fig. 4C). As expected, control AR.Q0 does not form insoluble 
species, even after T treatment (Fig. 4B). Because of its shorter polyQ size, the AR.Q39 is likely to 
be less prone to misfolding than Q112. It is conceivable that AR.Q39 may have a milder impact 
than AR.Q112 on the degradative system (compare Fig. 4A and Fig. 4C); but, after its T activation, 
AR.Q39 is still mostly processed by autophagy (see also later in Fig. 5A, 3-MA-treated samples). 
Also in this case, EHNA significantly reduced the formation of T-induced misfolded AR.Q39 
insoluble species to levels similar of that found in untreated AR.Q39 (Fig. 4C). No effects were 
seen on AR.Q0 (Fig. 4B). Interestingly, EHNA was also active on preformed inclusions (EHNA 
added 24 h after T treatment and maintained for other 24 h, Fig. S4), suggesting that these insoluble 
species are still dynamic at this stage. 
 Next, we enhanced the stressful conditions for motoneuronal cells by overexpressing 
proteins with transient transfection experiments, and used a polyQ tract of an intermediate size 
(Q46, which falls in the middle range of the pathological polyQ size described in SBMA patients91-
93). The aim was to verify whether, by producing a large amount of misfolded ARpolyQ insoluble 
species, the effect of dynein-mediated transport blockage was still present. As shown in Fig. 4D, 
overexpression of AR.Q46 correlated with an accumulation of a large fraction of T-induced 
misfolded ARpolyQ-insoluble species. No accumulation was observed in untreated AR.Q46 (Fig. 
4D; WB quantification in Fig. S3). The induction of ARpolyQ-insoluble species was similar (6-fold 
over control, Fig. 4A and Fig. 4D) in transiently transfected AR.Q46 (which aggregates in the 
cytoplasm20,25,31,32,69,86,87 and Fig. 4E) and in stably transfected AR.Q112 (which aggregates in the 
nucleus24,89,90). Even with the overexpressing conditions, dynein inhibition with EHNA reduced the 
accumulation of T-induced misfolded ARpolyQ-insoluble species to levels comparable to those 
found in untreated ARpolyQ (Fig. 4D). Dynein inhibition with EHNA partially affected also the 
overall levels of the various AR.Qn utilized in these experiments (see WBs in 4A, 4C and 4D and 
quantified in S4). In parallel, with the reduced aggregated forms of the various AR.Qn, the decrease 
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(even if relatively small) of the overall T-treated ARpolyQ levels in WB, which comprises all SDS-
soluble species (therefore, including the cytoplasmic ARpolyQ aggregates evaluated in IF), could 
be indicative of an increased clearance of the entire pool of the misfolded ARpolyQ fraction prior to 
its aggregation  (see below). Another possibility is that by preventing ARpolyQ concentration and 
aggregation, chaperones might have a larger time-window to properly fold the mutant protein. This 
increased efficiency of chaperone activity might enhance the fraction of ARpolyQ detected in WB. 
Unfortunately, the relative contribution between clearance and correct folding of the mutant 
ARpolyQ allowed by dynein blockage is unpredictable and modifications of this balance explain 
why we observed some fluctuaction of the total levels of ARpolyQ in WB after EHNA treatment. 
 Next, using IF microscopy we examined the effects of dynein inhibition on the formation of 
intracellular inclusions of mutant AR.Q46 in NSC34 cells (Fig. 4E). In line with our previous 
observations, the presence of ARpolyQ cytoplasmic aggregates (present only in about 30% of total 
transfected cells, Fig. 4F) correlated with a decreased nuclear bioavailability of the AR protein (Fig. 
4E, see second panel row).20 In cells treated with EHNA, only few cells still contain aggregates, and 
in general, AR is free to migrate into the nucleus (Fig. 4E, see sixth and seventh panel rows) at 
levels comparable to that observed in EHNA-untreated T-treated cells with no cytoplasmic 
aggregates, in which ARpolyQ normally translocated into the nucleus (Fig. 4E, see third and fourth 
panel rows). Thereby, EHNA treatment counteracted the formation of cytoplasmic ARpolyQ 
inclusions induced by T (Fig. 4E), and this resulted in a higher localization of diffuse AR in the 
nucleus (Fig. 4E, compare different exposure times utilized). Quantification data, performed using 
GFP-tagged ARpolyQ, showed that EHNA treatment almost completely counteracted the formation 
of inclusion in NSC34 cells after T treatment, since the total number of inclusions found after 
dynein inhibition was similar to that found in control (T-untreated) cells (Fig 4E, F).  
 The WB in Fig. 4D, which represents the average of cells with or without aggregates, shows 
that the overall levels of soluble AR remains similar in the 2 conditions, apart from the fraction that 
is insoluble (as observed in FRA of Fig. 4D), which is indeed counteracted by EHNA.   
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 Based on the observation reported above, we performed fractionation experiments using 
buffers characterized by increasing detergent power to analyse which particular insoluble fraction 
of ARpolyQ was mainly affected by EHNA treatment. The WB analysis on the solubilized pellets 
(see detailed scheme in Fig. S5), obtained after fractionation, revealed that cotreatment with EHNA 
and T increased the total levels of detergent-soluble AR.Q46, as compared to single treatment with 
T (Fig. 4G). This effect is possibly due to a shift between a phosphate-buffered saline (PBS)-Triton-
insoluble fraction (likely associated with accumulating ARpolyQ in IF and FRA, and evaluated in 
the SDS-soluble fraction, (third inset)) to the PBS-Triton-soluble fraction of ARpolyQ (Fig. 4G 
[upper 2 insets]). Indeed, dynein inhibition increased the overall ARpolyQ content in NSC34 cell 
lysates (particularly in the PBS soluble fraction), and it also led to the complete removal of the 
ARpolyQ species present in the SDS-formic acid (FA) fractions (Fig. 4G). Some variability was 
found in the SDS/FA fractions obtained from T-treated NSC34 and AR.Q46 cells not exposed to 
EHNA. This is likely due to biological variations in the transition from a dynamic SDS-soluble 
(likely aggresomes, Fig. 4G, third inset) to a stable SDS-insoluble (likely inclusions, Fig. 4G, fourth 
inset) status of the ARpolyQ aggregating materials, in cells. This transition may occur in very few 
samples, since in our experimental condition the amount of SDS-insoluble species is negligible. 
Notably, since EHNA should prevent ARpolyQ concentration and thus reduce aggregation of 
misfolded species, it also prevents the accumulation of all the species detected after fractionation. 
Collectively, these data suggest that EHNA prevents misfolded ARpolyQ accumulation into 
insoluble species, possibly by reducing their concentration, a process favoring protein-protein 
interaction and aggregation. 
 
Dynein inhibition reroutes ARpolyQ misfolded species from autophagy to proteasomal 
degradation.  
Autophagy is the main degradative pathway for the disposal of aggregates, which can inhibit 
proteasome activities by clogging the proteasome. Since dynein modulation does not impair basal 
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autophagy, but maintains ARpolyQ in a soluble (likely monomeric) state compatible with 
proteasomal clearance, we investigated whether autophagy or proteasome inhibition affect the 
antiaggregating activity of EHNA. Fig. 5A shows that in AR.Q39 cells, when dynein is functional, 
both the inhibition of autophagy, with the inhibitor 3-methyladenine (3MA), or of the proteasome, 
with the inhibitor MG132, increased the levels of T-induced misfolded ARpolyQ insoluble species 
retained on the membrane by FRA. These species are considerably more abundant after 3MA than 
MG132 treatment, supporting that autophagy is the main degradative pathway activated by the cells 
to clear mutant ARpolyQ. Notably, in the case of the stably expressed AR.Q39, we found that this 
misfolded protein is characterized by a low tendency to aggregate (than with overexpressed 
AR.Q46 or stably expressed AR.Q112), possibly with low impact on autophagy flux. Indeed, after 
pharmacological autophagy blockage, T-induced misfolded AR.Q39 insoluble species accumulated 
at levels similar to those found in stably expressed AR.Q112 (compare with Fig. 4A; WB 
quantification in Fig. S3) or in transiently expressed AR.Q46 (compare with Fig. 4D; WB 
quantification in Fig. S3) after T treatment (about 6-fold over the corresponding untreated 
ARpolyQ). Therefore, the polyQ size may influence both the rate of misfolded AR autophagic 
clearance and the intensity of autophagy impairment associated with the presence of insoluble 
species.  
 Conversely, in NSC34-expressing AR.Q39 cells cotreated with T and EHNA, we found that 
inhibition of autophagy with 3MA had a lower impact on the accumulation of misfolded ARpolyQ 
insoluble species (Fig. 5A, compare lane 4 and lane 10; WB quantification in Fig. S6), suggesting 
that other degradative pathways, including the proteasome, may become more relevant to ensure 
ARpolyQ disposal. Indeed, when the proteasome was inhibited by MG132, the effect of EHNA was 
reduced (Fig. 5A), suggesting that proteasome, but not autophagy, is required to clear misfolded 
ARpolyQ insoluble species when their transport and concentration to MTOC is inhibited. Our 
hypothesis is that, in basal conditions, the proteasome with its narrow barrel-shape cannot properly 
digest misfolded ARpolyQ insoluble aggregate-prone species and these are targeted for degradation 
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to autophagy in a dynein-dependent manner. Instead, the inhibition of misfolded protein transport 
might delay their aggregation, which requires protein-protein interaction, a step largely favored by 
the concentration of proteins achieved via dynein-mediated transport to specific intracellular sites 
(e.g., the MTOC or other sites were autophagosomes could be generated). The inhibition of 
misfolded protein concentration will maintain the ARpolyQ into soluble (likely) monomeric forms 
digestible by the proteasome.  
 To test this hypothesis, we used the proteasome reporter GFPu, which consists of the GFP 
protein tagged with a short degron (CL1) that routes the protein to the proteasome for 
degradation.86,94,95 Inhibition of the proteasome activity will result in GFPu accumulation into the 
cells.31,32,69,87 We have already shown, and confirmed here (Fig. 5B and quantification in Fig. S6), 
that the unactivated ARpolyQ, normally processed by the proteasome, may compete with GFPu for 
degradation, leading to a reduced GFPu clearance; instead, the formation of T-induced misfolded 
ARpolyQ insoluble species correlated with proteasome desaturation (and enhanced GFPu 
clearance). In addition, we found that dynein inhibition with EHNA improved the clearance of 
GFPu in all conditions tested, proving that misfolded protein transport blockage has no effect on 
proteasome activity (Fig. 5B). Moreover, EHNA treatment does not alter the proteasome 
chymotryptic activity (Fig. 5C), even in presence of control or T-treated ARpolyQ (Fig. 5D). We 
then verified whether dynein inhibition with EHNA perturbs the global-mediated transcriptional (or 
the translational) activity of NSC34 cells (please note that the expression of all WT and mutant 
genes utilized in this study are under the control of the CMV promoter).  As control, we evaluated 
the CMV-mediated transcription of the classical lacZ reporter gene measuring the encoded protein 
levels by testing the enzymatic β-galactosidase activity. In NSC34 cells, we found that the β-
galactosidase activity was not affected by treatment with EHNA (Fig. 5E) indicating that dynein 
inhibition does not impair trascriptional regulation of CMV regulated genes. In addition, we 
evaluated whether ENHA treatment has effects on cell survival by evaluating cell viability using the 
MTT assay. No differences in the levels of mitochondrial formazan formation were observed 
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between control and EHNA-treated NSC34 cells (Fig. 5F), suggesting that at this concentration 
EHNA has no toxic effects on immortalized motoneuronal cells. Together these results exclude that 
the reduced levels of misfolded ARpolyQ insoluble species observed after EHNA treatment are a 
consequence of reduced protein synthesis and/or increased cell death. Instead, combined with the 
higher rate of the proteasome-mediated degradation of the GFPu reporter, these results support the 
hypothesis that cells treated with EHNA promote the degradation of mutant ARpolyQ with a 
mechanism that is dynein- and autophagy-independent, and seems to be proteasome-dependent.  
 So far, our data indicate that inhibition of dynein-mediated delivery of misfolded ARpolyQ 
species prevents their accumulation and aggregation in motoneuronal cells. Dynein inhibition does 
not increase proteasomal activity, but rather it might facilitate misfolded ARpolyQ species 
recognition by the proteasome, a process that requires them to remain into the monomeric status. It 
is known that chaperones targeting misfolded proteins to autophagy for degradation (such as the 
HSPB8-BAG3 complex associated with HSPA8- and HSPA1A-bound substrates27-29,38,96) are 
generally upregulated when the proteasome is impaired. We asked whether EHNA tretament may 
activate an alternative chaperone response. We focused on BAG1, which, like BAG3, is a member 
of the BAG family of nucleotide exchange factors. In alternative to the HSPB8-BAG3 complex, 
BAG1 targets HSPA8- and HSPA1A-bound substrates to the proteasome for disposal.38,66,67,97 
Interestingly, after EHNA treatment, both Hspb8 (Fig. 6A) and Bag3 (Fig. 6B) mRNA levels 
remained unchanged in NSC34 cells, while Bag1 expression increased to over 2.5-fold supporting 
our working hypothesis (Fig. 6C). We next tested the functional significance of BAG1 upregulation 
on misfolded ARpolyQ clearance upon inhibition of dynein-mediated transport. Overexpression of 
BAG1 significantly reduced the accumulation of ARpolyQ retained on the cellulose acetate 
membrane (FRA, Fig. 6D; WB quantification in Fig. S6). Since BAG1 targets HSPA8- and 
HSPA1A-bound clients to the proteasome for degradation, we also evaluated whether the BAG1 
prodegradative function depends on a functional proteasome. In agreement with previous reports,97 
we found that proteasome inhibition prevented the BAG1 prodegradative activity on T-inducible 
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misfolded ARpolyQ insoluble species in NSC34 cells (Fig. 6E). Therefore BAG1, which is 
upregulated upon dynein inhibition with EHNA, enhances the proteasome-mediated degradation of 
ARpolyQ, limiting ARpolyQ aggregation linked to its "concentration" mediated by dynein, and 
protein "concentration" is required for selfassociation combined with insufficient autophagy for 
proper disposal. To further test this hypothesis, we downregulated endogenous Bag1 expression 
with a specific siRNA in NSC34 cells (Fig. 6F). Depletion of Bag1 in NSC34 cells expressing 
mutant ARpolyQ led to an increase in the levels of soluble and aggregated AR.Q46 species, both in 
absence and presence of T, supporting that BAG1 participates in ARpolyQ clearance. Depletion of 
Bag1 also significantly decreased the antiaggregation function of EHNA, since aggregated AR.Q46 
accumulated at higher levels as compared to control cells (Fig. 6G, compare lanes 3, 4 with lanes 7, 
8; WB quantification in Fig. S6). Notably, in agreement with our previous reports demonstrating 
that "nontoxic" and soluble T-untreated AR.Q46 is mainly processed by the proteasome,69,86,87 Bag1 
silencing increased the accumulation of unactivated AR.Q46.  
 Based on our findings we propose that, when the cells cannot transport misfolded ARpolyQ 
to the authophagosomes or aggresomes for its dynein-dependent autophagy-mediated degradation, 
they induce the expression of BAG1 to target these species to the proteasome for clearance. 
 
Rerouting of misfolded ARpolyQ in SBMA patient-derived iPSCs differentiated to neuronal 
and motoneuronal cells. 
To extend our observations to a more reliable model that better recapitulates the conditions present 
in human motoneurons of SBMA patients, we used a cell model alternative to NSC34 or PC12 cells, 
the motoneuronal cells obtained by differentiation of human induced pluripotent stem cells (iPSCs) 
to neuronal cells generated from SBMA patients. These cells have been cultured both in basal 
condition or exposed to T to induce ARpolyQ misfolding and toxicity. Differentiation of iPSCs was 
performed using the protocol described by Grunseich et al.98 (who developed the SBMA iPSCs), 
which allows to produce "bona fide" neuronal cells (all positive for neuronal markers including 
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TUBB3 and the axonal specific marker SMI312; Fig. 7A) and enriched of a variable population of 
motoneuronal cells which ranges from 15 to 23% (positive for motor neuron and pancreas 
homeobox 1 (MNX1/HB9) marker, Fig. 7A and quantification in Fig. 7B) of the total neuronal 
population. No glial cells were observed using the differentiation protocol adopted here.98 All iPSCs 
differentiated to neuronal cells from SBMA patients were also positive for AR expression, which 
translocated to nucleus upon T treatment (Fig. 7A). No major morphological variation was observed 
for neuronal and motoneuronal markers after T treatment (Fig. 7A and 7B). 
 Interestingly, after EHNA treatment, HSPB8 mRNA levels remained unchanged in iPSCs 
differentiated to neuronal cells (both untreated or T-treated) (Fig. 7C); BAG3 expression was mildly 
induced by T and to a lower extend by EHNA (Fig. 7D). EHNA treatment increased the expression 
of BAG1 of almost 1.5-fold and 2.5-fold in untreated and T-treated iPSCs differentiated to neuronal 
cells, respectively (Fig. 7E), further supporting that BAG1 upregulation represents a physiological 
stress response upon dynein inhibition. We next evaluated the impact of EHNA on the expression 
of key autophagy proteins in iPSCs differentiated to neuronal cells. After dynein inhibition (both in 
the absence and in the presence of T), the mRNA levels of SQSTM1 and TFEB (transcription factor 
EB) were increased (Figs. 7F, 7H), while LC3 levels remained unmodified after EHNA tretament 
(Fig. 7G). Notably, this upregulation of TFEB and SQSTM1 could be a cell attempt to restore an 
altered autophagic flux or to improve the intracellular lysosomal activity when transport of cargo to 
the autophagosomes is blocked. Conversely, BECN1 remained unchanged by dynein inhibition in 
iPSCs differentiated to neuronal cells (Fig. 7I). Combined these results strongly support that BAG1 
is a crucial physiologically activated PQC player.  
 
Effects of dynein inhibition on the clearance of other misfolded proteins associated with 
motoneuron diseases 
We next wanted to investigate whether the effects of dynein inhibition with EHNA described above 
are specific for the mutant misfolded ARpolyQ or are also exerted on other mutant proteins 
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responsible for another motoneuron disease similar to SBMA, the ALS. We selected 2 proteins that 
have been associated with ALS: i) the SOD1 enzyme (mutated in about 20% of fALS),99 and ii) a 
truncated form of TARDBP (TARDBP∆C, found in some fALS cases). Both mutant SOD1G93A and 
TARDBP∆C misfold and accumulate into cytoplasmic aggregates; as shown for ARpolyQ 31,32 their 
autophagic clearance can be enhanced by the HSPB8-BAG3 complex.28,29,32,96 In 2 different models 
of ALS, SOD1G93A transiently (Fig. 8A; WB quantification in Fig. S6) or inducible stably 
transfected (Fig. 8B) motoneuronal NSC34 cells, EHNA treatment resulted in a reduction of the 
total amount of misfolded mutant SOD1 insoluble species accumulating on cellulose acetate in FRA. 
Similar results were obtained in ALS models generated using the TARDBP∆C mutant (Fig. 8C; WB 
quantification in Fig. S7), demonstrating that dynein inhibition also affects the accumulation of the 
truncated fragment of TARDBP involved in ALS. As in the case of ARpolyQ, EHNA activity 
requires a functional proteasome activity, since its inhibition with MG132 prevented (even if not 
completely, see below) the clearance of mutant SOD1 (Fig. 8D; WB quantification in Fig. S7) and 
TARDBP∆C (Fig. 8E; WB quantification in Fig. S7), observed after dynein inhibition. Conversely, 
EHNA exerted its prodegradative effect on these 2 ALS-associated proteins when autophagy was 
inhibited by 3-MA treatment (Fig. 8D and 8E; WB quantification in Fig. S7). 
 Finally, we wanted to further extend these observations to other forms of proteinaceuos 
aggregates also involved in motoneuron diseases, but structurally totally distinct from the misfolded 
proteins studied above. We analyzed one out of 5 potentially neurotoxic dipeptides generated by 
RAN-translation from the C9ORF72 transcript containing an expanded exanucleotide repeat 
(GGGGCC)n linked to several fALS (and some sALS) cases and in many cases of frontotemporal 
dementia.100-106 To produce the peptide selected (the dipeptide [glycine-proline], polyGP) we used a 
synthetic DNA in order to avoid multiple dipeptide production and/or (GGGGCC)n-associated 
RNA toxicity.107 The polyGP is not produced in basal physiological conditions and it is likely that 
the polyGP has no propensity to acquire a natural conformation. It is expected that its structure is 
likely to be unrelated to the aberrant conformation generated by the mutant misfolded proteins. 
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Despite this, also the polyGP is prone to aggregate, and accumulates in neurons into intracellular 
insoluble inclusions. The polyGP is cleared by the PQC system,107 an aspect that we confirmed in 
immortalized motoneurons, where both proteasome or autophagy inhibition (with MG132 or 3MA, 
respectively) increased the accumulation of insoluble polyGP species evaluated with FRA (Fig. 9; 
WB quantification in Fig. S7). In line with our previous data, dynein inhibition led to a reduction of 
polyGP insoluble species even when autophagy is blocked with 3MA. In the case of polyGP, the 
antiaggregant effect of ENHA was not completely counteracted by the cotreatment with the 
proteasome inhibitor MG132, even if more than 50% of total insoluble polyGP species accumulated 
with proteasome blockage. PolyGP is characterized by a very high proteasomal turnover. Indeed, 
we found a 30-fold increase of insoluble species accumulating with MG132 treatment. Since 
MG132 only inhibits the chymotryptic proteasomal activity,108,109 it is likely that the polyGP will be 
processed also using the postacidic or tryptic activities of the proteasome, which may explain the 
partial inhibitory effect obtained by treatment with MG132. Alternatively, as already postulated 
above, other degradative pathways (such as chaperone mediated autophagy [CMA]) could be 
involved in the polyGP clearance, as well as for ARpolyQ, mutant SOD1, TARDBP in which 
proteasome inhibition did not always correlate with a full blockage of EHNA effects. 
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DISCUSSION  
 
Here, we analyzed how the inhibition of the dynein-mediated retrograde transport of misfolded 
proteins to MTOC affects their intracellular aggregation and clearance. Our approach was based on 
previous data showing that misfolded protein clearance is enhanced by their interaction with the 
complex HSPB8-BAG3,28,29 a complex that, in conjunction with HSPA8 and HSPA1A, recruits 
STUB1 to allow misfolded substrate ubiquitination and SQSTM1 mediated insertion into 
autophagosomes at the MTOC.39 BAG3 interacts with the YWHA/14-3-3 protein and dynein, 
which transports the complex (misfolded protein-HSPB8-BAG3-HSPA8-STUB1) to the 
MTOC.73,74 Given this evidence, we were expecting that dynein inhibition correlated with an 
overall increased accumulation of insoluble and aggregated misfolded proteins inside the cells. 
Instead, in motoneuronal cells, we found that depletion or chemical inhibition of dynein decreased 
the aggregation of misfolded proteins maintaining them in a soluble state competent for 
proteasomal degradation. In fact, upon dynein inhibition, all misfolded proteins we analyzed were 
preferentially targeted to the proteasome for degradation, while autophagy inhibition had no or mild 
impact on their total levels and aggregation. Dynein inhibition did not impair basal autophagy, 
which appeared to be very limited in basal conditions in our cells. Conversely, dynein inhibition 
reduced activation of autophagy stimulated by trehalose, mostly through changes at the 
transcriptional level. 
 Misfolded proteins species altered autophagy, but dynein blockage reduced their disposal 
via autophagy. Under these conditions, the autophagy markers, HSPB8 and BAG3 were not induced, 
while BAG1 was upregulated. BAG1 is a HSPA8 cochaperone which both assists HSPA-mediated 
protein folding (by enhancing its activity as nucleotide exchange factor),38,66,67 and targets HSPA8 
client proteins to proteasomal degradation66,97,110-113 (and under specific circumstances even to 
CMA114). Our results suggested that BAG1 represents a crucial player by routing misfolded 
proteins to proteasome when their transport to the MTOC is blocked. In line, overexpression of 
 23
BAG1 in cells with deficient or inhibited dynein allowed a more efficient proteasomal degradation 
of misfolded species that were accumulating in a monomeric, or small oligomeric and soluble forms, 
rather than as aggregates because of the inhibition of their concentration at the MTOC (a process 
that facilitates aggregation).  
 Conversely, because proteasome inhibition leads to upregulation of BAG3 and HSPB8, 
which reroute (poly)-ubiquitinated and misfolded clients towards autophagy for degradation,28,29,38 
here we propose that, in cells where dynein-mediated transport is inhibited, BAG1 upregulation and 
its mediated rerouting of misfolded substrates to the proteasome represent an alternative mechanism 
activated by cells to maintain protein homeostasis. Molecularly, this may be explained by the fact 
that BAG1 possesses an ubiquitin-like domain for targeting of the HSPA8-bound client to the 
proteasome, while BAG3 has no ubiquitin-like domains,37,115-117 but its interaction with YWHA/14-
3-3-dynein permits the transport of misfolded proteins to the MTOC for autophagy clearance.70,73,74 
Therefore, when misfolded proteins cannot be efficiently transported to autophagosomes, the cells 
upregulate an alternative chaperone system, that ensures enhanced proteasomal misfolded proteins 
clearance preventing their aggregation. In line, pharmacological autophagy blockage did not alter 
the effect of dynein inhibition on misfolded protein clearance. The prevention of misfolded protein 
concentration also might reduce protein-protein interaction, which is essential for aggregation, 
favoring the maintenance of the monomeric status of the protein. This might allow a larger time 
window for proper protein folding, since BAG1 also acts as a nuclear exchange factor for HSPA, 
enhancing and optimizing its chaperone activity and this acts alternatively to protein rerouting to 
the proteasome. This may explain why we occasionally found variations in the total levels of 
soluble ARpolyQ (measured in WB), as compared to the levels of insoluble ARpolyQ (detected 
with FRA), after EHNA treatment. Even if both folding and degradation processes may coexist, our 
data suggest that the role of degradation prevails on the refolding. Here we propose that dynein 
inhibition requires 2 steps: 1) control of aggregation and 2) routing of soluble clients towards the 
proteasome (or to proper folding) in a BAG1-assisted manner. In fact, under these conditions, 
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insertion of aggregate-prone proteins into an aggresome is blocked 46,118 and the aggregate-prone 
substrates are maintained in a state that is competent for degradation by the proteasome.119   
 Notably, also preformed (but still dynamic) aggregates can be redissolved into soluble 
proteasomal digestible proteins, since EHNA was also effective when added 24 h after ARpolyQ 
inclusions induction with T. The rerouting system here described might also have impact on nuclear 
inclusions. Indeed, we showed that also using an ARpolyQ with a very long size (Q112), which is 
capable of generating nuclear aggregates, resembling those typically found in SBMA patients,24,25 
dynein blockage correlated with a reduced accumulation of insoluble species, possibly associated 
with enhanced proteasomal clearance taking place both in nuclear and cytoplasmic compartments. 
 Altogether, these data shed light on the importance of dynein-mediated transport in the 
intracellular routing of misfolded proteins to their preferred degradative system, and are in line with 
previous observations showing that the disruption of microtubules with nocodazole inhibits 
aggresome formation in cells expressing the exon 1 of mutant HTT (huntingtin) or 
ARpolyQ.46,118,120 These studies also showed that prevention of aggregate formation correlates with 
an increased toxicity of the 2 misfolded proteins analyzed (HTT-polyQ and ARpolyQ), supporting 
the notion that aggresomes may have a protective activity in their earlier stages of formation.20-22 In 
our study, a less invasive and more specific approach was used to block misfolded protein 
concentration at the MTOC, where aggresomes are formed.121,122  
 Therefore, it is likely an alteration of the fine equilibrium of protein routing that may affect 
the release or accumulation of neurotoxic species, rather than the impairment or overwhelming of a 
single degradative pathway. These pathways may also include CMA. Indeed, BAG1, by interacting 
with HSPA8, might also direct misfolded proteins to CMA for clearance,114,119,123 Unfortunately, no 
selective inhibitors are available for CMA and we were unable to evaluate its contribution in the 
degradation of misfolded species after dynein impairment. 
 A second aspect that emerges from the data here presented is that the role of dynein in 
mediating the transport of autophagosomes to lysosomes to allow their fusion may be secondary to 
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the cargo delivery to the MTOC. In fact, we did not find major problems in misfolded protein 
clearance even if autolysosome formation was impaired in parallel to transport blockage. As stated 
above the activity of this pathway is made irrelevant by the BAG1-mediated routing of misfolded 
proteins to the proteasome (and eventually CMA), and the role of dynein in cargo transport to 
phagophores precedes that in autophagosome and lysosome fusion. 
 These data apparently contrast with the observations obtained in transgenic mice carrying 
missense point mutations in the cytoplasmic dynein heavy chain. Heterozygous mice are 
characterized by progressive motoneuron loss, but without accumulation of proteinaceous material 
in affected cells. Homozygous mice suffer motoneuronal degeneration with accumulation of Lewy-
like inclusion bodies.60 In addition, cytoplasmic dynein is activated by the ubiquitously expressed 
dynactin, and mutation in the DCTN1/p150Glued subunit of dynactin, which prevents dynein 
activation, causes specific motoneuron loss, with the appearance of DCTN1/p150Glued protein 
aggregates124-126 (see also ref. 127 for an extensive review on dynein mutations in human and mice). 
However, different mice in which dynein and dynactin functions are altered (either because of 
dynein mutations (Legs at odd angles),65,128 or because of neuron-specific expression of Bicaudal 
D2 N-terminus129) causing an ALS-like phenotype, have improved life span when crossed with 
transgenic SOD1G93A mice.65,128,129 The phenotype of these double transgenic mice is also 
ameliorated when compared to the single transgenic mice expressing the mutant SOD1 protein. 
Therefore, while dynein mutations per se are deleterious to motoneurons, it is possible that dynein 
may contribute to exacerbate the adverse effects exerted by mutant misfolded proteins on 
motoneurons. It is likely that this adverse effect of dynein is due to a routing of misfolded proteins 
at the MTOC (which escape proteasome-mediated degradation) that induces aggregation and 
possibly autophagic flux blockage.  
 While these data may not be readily translated into possible therapeutic approaches, they 
could help to better understand the molecular mechanisms at the basis of misfolded protein 
clearance and the way that motoneurons select specific pathways of degradation for a given protein. 
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MATERIALS AND METHODS 
Chemicals 
Erythro-9-(2-Hydroxy-3-nonyl) adenine hydrochloride (EHNA; Sigma-Aldrich, E114), Z-Leu-Leu-
Leu-al (MG132; Sigma-Aldrich, C2211), trehalose (Sigma-Aldrich, T9531), 3-methyladenine 
(3MA; Selleckchem, S2767), ammonium chloride (Euroclone, EMR089500). 
 
Plasmids and siRNA 
The plasmids coding for AR.Q23, AR.Q46, GFP-AR.Q48 and pCI-HSPB8 are routinely used in our 
laboratory and they have been previously described.20,30-32 The pcDNA/HA-BAG1 plasmid coding 
for the protein BAG1 was kindly provided by Prof. Harm H. Kampinga (University of Groningen, 
Groningen, The Netherlands).67,130 The plasmid expressing the proteasome function reporter GFPu 
was kindly provided by Prof. Ron Kopito (Stanford University, Stanford, CA, USA).94 The pCMV-
β plasmid, encoding β-galactosidase (Clontech, 6177-1) was used to evaluate EHNA effect on total 
protein expression levels. The pcDNA3-wtSOD1 and pcDNA3-SOD1G93A plasmids expressing 
human wtSOD1 or mutant SOD1G93A were kindly provided by Dr. Caterina Bendotti (Mario Negri 
Institute, Milano, Italy).131 pFLAG-FL TDP-43 (TARDBP), and pFLAG-TDP-43∆C (TARDBP∆C) 
plasmids, expressing FLAG-tagged full-length human TARDBP and an N terminal truncated at 
residue 261 (lacking the C-terminal region), respectively, were kindly provided by Dr. Emanuele 
Buratti (International Centre for Genetic Engineering and Biotechnology, Trieste, Italy).132,133 
pCMV-Flag-polyGP-V5-His plasmid encoding the polyGP dipeptide was kindly provided by Prof. 
Daisuke Ito (Keio University School of Medicine, Tokio, Japan).107 The pcDNA3 (Life 
Technologies, V790-20) plasmid was used to normalize for transfected plasmid DNA amount. The 
pEGFPN1 (Clontech, U55762) plasmid was used to evaluate transfection efficiency in experiments 
involving transient transfections. pcDNA5/TO-GFPAR.Q0 and pcDNA5/TO-GFPAR.Q39 
plasmids were used to obtain stable and inducible SBMA cell models and were constructed by 
cloning the sequence coding for GFPAR.Q0 and GFPAR.Q39 into NheI and XbaI sites of 
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pcDNA5/TO (Life Technologies, V103320), previously modified with insertion of BamHI and 
NheI sites. 
 To silence endogenous Dync1h1 and Bag1 expression we used custom siRNA duplex: [5’-
GGGUAAAGCUAGAGAGAAUUU-3’ (sense)], [5’-AUUCUCUCUAGCUUUACCCUU-3’ 
(antisense)] for Dync1h1 and [5’-AAGAAGAGGUUGAGUUAAAUU-3’ (sense)], [5’-
UUUAACUCAACCUCUUCUUUU-3’ (antisense)] for Bag1 (Dharmacon, Thermo Scientific Life 
Sciences Research). 
 
Cell cultures and transfection  
The immortalized motoneuronal cell line NSC34134,135 is routinely used in our laboratory and has 
been transfected with Lipofectamine (Life Technologies, 18324020)-TRF (transferrin; Sigma-
Aldrich, T8158), as previously described,20,25,136 using 0.6 μg of plasmid DNA, 4 μL of TRF 
solution and 2 μL of Lipofectamine (amount for 1 well of a 12-well multiwell plate). siRNA 
transfection was performed with Lipofectamine 2000 (Life Technologies, 11668019), using 40 
pmol of target RNA and following the manufacturer’s instructions. 
 Inducible stably transfected NSC34-GFPAR.Q(n) cell lines were obtained by transfecting 
pcDNA5/TO-GFPAR.Q(n) into TR4 NSC34 cell line stably transfected with pcDNA6/TR encoding 
for tetracycline repressor, kindly provided by Dr. Enrico Garattini (Mario Negri institute, Milan, 
Italy), and were routinely maintained as described previously.137  
 Rat adrenal pheochromocytoma (PC12) cells stably transfected with the plasmid encoding 
AR.Q10 and AR.Q112 express AR under the control of a Tet-On promoter, responsive to 1 µg/mL 
of doxycycline. PC12-AR.Q(n) cells have been produced and kindly provided by prof. Diane Merry 
(Thomas Jefferson University, Philadelphia, PA, USA) and were routinely maintained as described 
by Walcott et al., 2002.89 
 iPSCs were obtained in the lab of Dr. Kennet Fischbeck (by Dr. Christopher Grunseich) at 
NIH, Bethesda, MD, USA from fibroblasts of SBMA patients (SB6MP2 clone) and generated by 
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POU5F1/Oct4, KlF4, SOX2 and MYC/c-Myc transfection. iPSCs were cultured in Essential 8 
medium (Life Technologies, A1517001) and differentiated into motoneurons as described 
previously.98 Briefly, iPSCs were grown to 80% confluency, then digested with collagenase IV 
(Life Technologies, 17104019), scraped off of the dish, and replated into ultra-low attachment 
dishes (Corning, 3262) in KSR (Life Technologies, 10828028)-based medium, with 20 ng/ml FGF 
(ORF genetics, 01-A01110), 20 μM ROCK-I (Selleckchem, S1049), 10 μM SB431542 (Stemgent, 
04-0010), 0.2 μM LDN193189 (Stemgent, 04-0074), to allow embryo bodies (EBs) formation. EBs 
were transitioned to a KSR-free medium at day 3. Retinoic acid (1 μM; Sigma-Aldrich, R2625) was 
added at day 5 to direct cell differentiation into the rostral spinal cord phenotype. Smoothened 
agonist (1 μM; Merck Millipore, 566660) and 0.5 μM purmorphamine (Caymanchem, 10009634) 
were added at day 7 to ventralize the differentiating population. The EBs were dissociated at day 14 
and plated at 150,000 cells/well on 12-well multiwell plates for RNA extraction or at 50,000 
cells/well on 24-well multiwell plates for immunofluorescence (IF). Plates were coated with poly-
D-lysine (Sigma-Aldrich, P7405) and laminin (Life Technologies, 23017015). Differentiated-
motoneurons were allowed to grow for an additional 10 days in neurobasal medium (Life 
Technologies, 21103049) with 25 μM glutamate (Sigma-Aldrich, 1446600), 0.4 μg/ml ascorbic acid, 
10 ng/ml GDNF (PeproTech, 167450-10), 10 ng/ml CNTF (PeproTech, 167450-13), 1 μg/ml 
laminin, B-27 (Life Technologies, 17504044), N2 (Life Technologies, 17502048), nonessential 
amino acids (Euroclone, ECB3054D), and pen/strep/glutamine (Euroclone). Motoneuronal cells 
were treated with ethanol or 10 nM T and/or 100 μM EHNA for the last 48 h previous to analysis. 
 Stably transfected NSC34-wtSOD1 and NSC34-SOD1G93A cell lines have been produced 
and kindly provided by Prof. Maria Teresa Carrı` (Università Roma Tor Vergata, Roma, Italy). 
These cell lines express MYC-tagged human wtSOD1 or SOD1G93A and were routinely maintained 
as described by Ferri and colleagues.138 
 In the experiments involving steroid hormone treatments, the serum was replaced with 
charcoal-stripped serum, to eliminate endogenous steroids.25,139,140 The effects of treatments (T, 
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EHNA, 3MA, MG132, etc.), for each mutant protein considered, were analyzed on 3 (4 for the RT-
qPCR analysis) independently cultured, transfected and treated samples (considered as independent 
variables (n)). 
 
mRNA expression analysis  
NSC34 cells were plated at 180,000 cells/well (4 wells for each condition to be tested; n=4) in 6-
well multiwell plates, allowed to growth for 24 h and then treated with 100 μM EHNA and/or with 
100 mM trehalose, or with DMSO (used as negative control). Forty-eight h after treatments, cells 
were harvested and centrifuged 5 min at 100 x g at 4°C; the pellets were resuspended in 300 μL of 
TRI Reagent (Sigma-Aldrich, T9424) and total RNA isolated according to manufacturer’s 
instructions. RNA quantification was carried out by absorbance at 260 nm. Total RNA (1 μg) was 
treated with DNAse I (Sigma-Aldrich, AMPD1), and reverse transcribed into cDNA using the 
High-Capacity cDNA Archive Kit (Life Technologies, 4368813) according to the manufacturer’s 
protocol. All primers for real-time PCR were designed using the program Primer 3.  
 The primers were synthesized by MWG Biotech (Ebersberg, Germany) with the following 
sequence: Map1LC3-B: 5′-CGT CCT GGA CAA GAC CA-3′ (forward), 5′-CCA TTC ACC AGG 
AGG AA-3′ (reverse); Sqstm1: 5′ -AGG GAA CAC AGC AAG CT-3′ (forward), 5′ -GCC AAA 
GTG TCC ATG TTT CA-3′ (reverse); Rplp0: 5’-GGT GCC ACA CTC CAT CAT CA-3’ (forward), 
5′ -AGG CCT TGA CCT TTT CAG TAA GT-3′ (reverse); Hspb8: 5’-ATA CGT GGA AGT TTC 
AGG CA-3’ (forward), 5′ -TCT CCA AAG GGT GAG TAC GG-3′ (reverse); Bag3: 5’-ATG GAC 
CTG AGC GAT CTC A-3’ (forward), 5′ -CAC GGG GAT GGG GAT GTA-3′ (reverse); Bag1: 5’-
GAA ACA CCG TTG TCA GCA CT-3’ (forward), 5′ -GCT CCA CTG TGT CAC ACT C-3′ 
(reverse); HSPB8: 5’- AGA GGA GTT GAT GGT GAA GAC C-3’ (forward), 5′-CTG CAG GAA 
GCT GGA TTT TC-3′ (reverse); BAG1: 5’-TTT AGA GCA GCC CGA GTG AT-3’ (forward), 5′- 
GAC AGC AGA CAG CCA ACA AA-3′ (reverse); BAG3: 5’- GGG TGG AGG CAA AAC ACT 
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AA-3’ (forward), 5′-AGA CAG TGC ACA ACC ACA GC-3′ (reverse); SQSTM1 5’- CCA GAG 
AGT TCC AGC ACA GA-3’(forward), 5’- CCG ACT CCA TCT GTT CCT CA-3’(reverse); 
MAP1LC3B 5’- CAG CAT CCA ACC AAA ATC CC-3’(forward), 5’- GTT GAC ATG GTC AGG 
TAC AAG-3’(reverse); TFEB 5’- CAA GGC CAA TGA CCT GGA C-3’(forward), 5’- AGC TCC 
CTG GAC TTT TGC AG-3’(reverse); BECN1 5’-ATG CAG GTG AGC TTC GTG TG-
3’(forward), 5’-CTG GGC TGT GGT AAG TAA TGG A-3’(reverse); RPLP0: 5’-GTG GGA GCA 
GAC AAT GTG GG-3’ (forward), 5′ -TGC GCA TCA TGG TGT TCT TG-3′ (reverse). 
 The evaluated efficiency of each set of primers was close to 100% for both target and 
reference gene. Real-time PCR was performed using the CFX 96 Real-Time System (Bio-Rad, 
Hercules, CA, USA) in a 10-μL total volume, using the iTaq SYBR Green Supermix (Bio-Rad, 
1725124), and with 500 nM primers. PCR cycling conditions were as follows: 94°C for 10 min, 40 
cycles at 94°C for 15 sec and 60°C for 1 min. Melting curve analysis was performed at the end of 
each PCR assay as a control for specificity. Data were expressed as Ct values and used for the 
relative quantification of targets with the ∆∆Ct calculation.141,142 To exclude potential bias due to 
averaging, data have been transformed through the equation 2−∆∆Ct to give N-fold changes in gene 
expression, all statistics were performed with ∆Ct values. Each experiment was carried out with 4 
independent samples (n=4).  
 
Western blot (WB) analysis and filter retardation assay (FRA)  
NSC34 or PC12 cells were plated in 12-well multiwell plates at 80,000 cell/well (3 wells for each 
condition to be tested; n=3). 24 h after plating, cells were transfected as previously described or 
induced with 1 µg/mL doxycycline, and AR activation was induced by 10 nM T treatment for 48 h. 
Inhibition of dynein ATPase activity was performed by 100 μM EHNA for 48 h. In experiments 
involving autophagy blockage or induction, 10 mM 3MA for the last 48 h, 20 mM NH4Cl for the 
last 1.5 h or 100 mM trehalose for the last 48 h were added to the cells. Proteasome inhibition was 
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performed by 10 µM MG132 treatment for the last 16 h (overnight treatment). Seventy-two h after 
plating, cells were harvested and centrifuged 5 min at 100 x g at 4°C; the cell pellets were 
resuspended in PBS (Sigma-Aldrich, P4417) added of the protease inhibitor cocktail (Sigma-
Aldrich, P8340) and homogenized using slight sonication to lyse cells and nuclei as previously 
described.86,139 Total proteins were determined with the bicinchoninic acid method (BCA assay; 
Euroclone, EMP014500).  
 WB was performed on 7.5% (to detect AR protein), 12% (to detect SOD1 and TARDBP 
proteins) or 15% (to detect LC3 and SQSTM1/p62 proteins) SDS-polyacrylamide gel 
electrophoresis loading 15 µg of total proteins. Samples were then electrotransferred to 
nitrocellulose (Bio-Rad, 1620115) or PVDF (polyscreen transfer membrane; Amersham, 10600023) 
using a semidry transfer apparatus (Trans-Blotw TurboTM Transfer System; Bio-Rad). The 
membranes were treated with a blocking solution containing 5% nonfat dried milk powder 
(Euroclone, EMR180500) in Tris-buffered saline with Tween 20 (0.01%; Sigma, P1379) (TBS-T; 
Tris base 20 mM, NaCl 140 mM, pH 7.6) for 1 h and then incubated with one of the following 
primary antibodies: (a) rabbit polyclonal AR-H280 (dilution 1:3,000) to detect wtAR and ARpolyQ 
(Santa Cruz Biotchnology, sc-13062); (b) rabbit polyclonal anti-LC3A/B (dilution 1:4,000; Sigma-
Aldrich, L8918); (c) rabbit polyclonal anti-SQSTM1 (dilution 1:4,000; Abcam, ab91526); (d) rabbit 
polyclonal anti-dynein heavy chain (dilution 1:1,000; Santa Cruz Biotchnology, sc-9115); (e) rabbit 
polyclonal anti-GFP HRP conjugated (dilution 1:15,000; Vector Laboratories, MB-0712); (f) rabbit 
polyclonal anti-HA (dilution 1:1,000; Santa Cruz Biotchnology, sc-7392) to detect overexpressed 
BAG1; (g) rabbit polyclonal anti-BAG1 (dilution 1:1,000; Santa Cruz Biotchnology, sc-939) to 
detect endogenous BAG1; (h) rabbit polyclonal Cu/Zn SOD (1:1,000; Enzo Life Science, ADI-
SOD-100) to detect SOD1; (i) mouse polyclonal anti-flag M2 (dilution 1:1,000; Sigma-Aldrich, 
F1804) to detect TARDBP; (j) mouse monoclonal anti-TUBA(dilution 1:4,000; Sigma-Aldrich, 
T6199); (k) rabbit polyclonal anti-GAPDH (1:4,000; Santa Cruz Biotchnology, sc-25778). 
Immunoreactivity was detected using the following secondary peroxidase-conjugated antibodies: 
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goat anti-rabbit (dilution 1:20,000; Santa Cruz Biotchnology, sc-2004); goat anti-mouse (dilution 
1:20,000; Santa Cruz Biotchnology, sc-2005). Signals were revealed by chemiluminescence 
detection kit reagents (Clarity™ Western ECL Blotting Substrate; Bio-Rad, 170-5060). The same 
membranes were subsequently processed with different antibodies to detect the levels of different 
proteins in the same sample, after stripping for 20 min at room temperature (StripABlot; Euroclone, 
EMP100500).  
 FRA was performed using a Bio-Dot SF Microfiltration Apparatus (Bio-Rad). Six µg of the 
total SOD1, TARDBP and polyGP proteins or 1.5 µg of the total AR.Q(n) were filtered through a 
0.2-µm cellulose acetate membrane (Whatman, 100404180). Slot-blots were probed as described 
for WB. 
 A ChemiDoc XRS System (Bio-Rad, Hercules, California, USA) was used for the image 
acquisition of WB and FRA. Optical density of samples assayed with WB or FRA was detected and 
analyzed using the Image Lab software (Bio-Rad). Statistical analyses have been performed using 
the relative optical densities defined as the ratio between optical densities of each independent 
biological sample (n=3) and the mean optical density of control samples.  
 
Protein Fractionation 
Protein fractionation of NSC34 transfected with AR.Q46 was modified from Koyama et al.143 The 
cells were harvested and centrifuged 5 min at 100 g at 4°C, then resuspended in PBS containing 
protease inhibitor cocktail and homogenized using slight sonication. The homogenates were 
centrifuged at 16,000 g for 10 min at 4°C. Subsequently, the supernatants were collected as the 
PBS-soluble fraction. The pellets were resuspended in 1% Triton X-100 (TX)-PBS and 
homogenized using slight sonication. After centrifugation at 16,000 g for 10 min at 4°C, the 
supernatants were collected as the TX-soluble fraction. Next, the pellets were resuspended in 5% 
SDS (Fisher Molecular Biology, FS0109)-PBS and homogenized using slight sonication. After 
centrifugation at 16,000 g for 10 min at 4°C, the supernatants were collected as the SDS-soluble 
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fraction. Next, the pellets were resuspended in 88% formic acid/PBS and homogenized using slight 
sonication. After centrifugation at 16,000 g for 10 min at 4°C, the supernatants were collected as 
the FA-soluble fraction. (See also Fig. S5 in the supplementary materials). Protein concentrations of 
PBS and TX fractions were measured by a BCA protein assay (Euroclone, EMP014500) and 15 μg 
were loaded for SDS-polyacrylamide gel electrophoresis. For SDS and FA fractions (10 μL) were 
loaded for SDS-polyacrylamide gel electrophoresis. All fractions were analyzed as described for 
WB. 
 
Microscopy analyses on NSC34 cells  
NSC34 cells were plated in 12-well multiwell plates containing coverslips at 70,000 cells/well 
density, transiently transfected with the plasmid coding for AR.Q46 or HSPB8 or with Dync1h1 
siRNA as previously described. AR activation was induced by 10 nM T treatment for 48 h, 
inhibition of dynein ATPase activity was performed by treatment with 100 μM EHNA for 48 h. In 
experiments involving autophagy induction, 100 mM trehalose was added to the cells for the last 48 
h. Then, the cells were fixed and processed as previously described.95  
 SBMA patient-derived iPSCs cells, differentiated to neuronal cells as described above, were 
plated in 24-well multiwell plate containing coverslips coated with laminin and poly-D-lysine at 
50,000 cell/well density, and allowed to growth and differentiate to motoneuronal cells for 10 days. 
AR activation was induced by 10 nM T treatment for the last 48 h prior to fixation. Inhibition of 
dynein ATPase activity was performed by treatment with 100 μM EHNA for the last 48 h prior to 
fixation. Then the cells were fixed and processed as described previously.98 The following primary 
antibodies were used to analyze protein distributions in NSC34: rabbit polyclonal AR-H280 
antibody (1:500; Santa Cruz Biotchnology, sc-13062) in TBS-T with 5% nonfat milk, rabbit 
polyclonal anti-LC3 antibody (1:500, Sigma-Aldrich, L8918) in TBS-T with 5% nonfat milk, and 
rabbit polyclonal anti-SQSTM1 antibody (1:500; Abcam, ab91526) in TBS-T with 5% nonfat milk. 
The following primary antibodies were used to analyze protein distributions in differentiated 
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SBMA patient-derived iPSCs: rabbit polyclonal ARN20 antibody (1:200; Santa Cruz 
Biotechnology, sc-816) in 3% BSA (Sigma, A7030)-PBS-0.1% Tween 20, mouse monoclonal 
MNX1/HB9 antibody (1:200; DSHB, 81.5C10) in 3% BSA-PBS-0.1% Tween 20, rabbit polyclonal 
TUBB3 (1:200; Cell Signaling Technology, 5568) in 3% BSA-PBS-0.1% Tween 20, mouse 
monoclonal SMI312 antibody (1:1000; Sternberg Monoclonals Incorporated, SMI312) in 3% BSA-
PBS-0.1% Tween 20. Secondary antibodies were: Alexa Fluor 488 anti-rabbit (1:1000; Life 
Technologies, A11070) and Alexa Fluor 594 anti-mouse (1:1000; Life Technologies, A11072) in 
3% BSA-PBS-0.1% Tween 20. Cells were stained with DAPI to visualize the nuclei. Images were 
acquired with i) Axiovert 200 microscope (Zeiss Instr., Oberkochen, Germany) equipped with 
FITC/TRITC/DAPI filters and combined with a Photometric Cool-Snap CCD camera (Ropper 
Scientific, Trenton, NJ, USA), phase contrast image was used to evaluate the morphology. Images 
were processed using the Metamorph software (Universal Imaging, Downingtown, PA, USA). ii) 
LSM510 Meta system confocal microscope (Zeiss, Oberkochen, Germany) and images were 
processed with the Aim 4.2 software (Zeiss). 
 
Proteasome activity 
Proteasome chymotryptic assay was performed as described by Allen et al.144 NSC34 cells were 
plated in 6-well multiwell plates at 180,000 cells/well (4 wells for each condition to be tested; n=4). 
Where indicated, cells were trasfected with plasmid coding for AR.Q46, as described above, and 
treated with 10 nM T for 48 h, 100 μM EHNA for 48 h, 10 μM MG132 for the last 16 h, or DMSO 
for 48 h. Cells were washed with ice-cold PBS and then harvested and centrifuged at 100 x g for 5 
min, at 4°C. Pellets resuspended in 0.3 mL of proteasome extract buffer (20 mM Tris HCl, pH 7.4, 
containing 0.1 mM EDTA, 1 mM 2-mercaptoethanol, 5 mM ATP [Sigma, A1852], 20% v/v 
glycerol, and 0.04% v/v Nonidet P-40 [Sigma, 98379]) were homogenized by 10 passages through a 
21-gauge needle, and then centrifuged at 12,000 x g for 15 min at 4°C, saving the supernatant. Total 
proteins were determined with BCA protein assay. Proteasome assay reaction mixtures consisted of 
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50 mM HEPES-KOH, pH 8.0, containing 5 mM EGTA, 100 μg of cell protein extract per mL of 
assay reaction. Chymotryptic proteasome substrate conjugated with amidomethylcoumarin (AMC), 
the peptide N-Suc-LLVY-AMC (Sigma, S6510), was added to the mix at 50 μM and incubated at 
37°C for 45 min. The resulting fluorescence was measured at 340 nm excitation and 460 nm 
emission using a plate spectrofluorimeter (Enspire, Perkin Elmer, MA, USA). 
 
Cell viability assay 
The 3-(4,5-dimethyl-2-thiazolyl)-2,5 diphenyl-2H-tetrazolium bromide (MTT; Sigma-Aldrich, 
M2128)-based cell proliferation assay (MTT assay) was carried out on NSC34 cells 24 or 48 h after 
treatment with 100 μM EHNA, and performed in 24-well multiwell plates at 45,000 cells/well (6 
wells for each condition to be tested; n=6). MTT solution was prepared at 1.5 mg/mL in DMEM 
without phenol red and was filtered through a 0.2-μm filter. Then, the culture medium was removed 
from the plate and 300 μL of MTT solution was added into each well. Cells were incubated for 30 
min at 37°C with 5% CO2, 95% air and complete humidity. After 30 min, 500 μL of 2-propanol was 
added into each well and the precipitates were suspended. The optical density (OD) of the wells was 
determined using a plate reader at a wavelength of 550 nm. 
 
β-galactosidase assay 
NSC34 cells were plated in 24-well multiwell plates at density of 40,000 cells/well (6 wells for each 
condition to be tested; n=6) and transfected with 0.4 μg of pCMV-βgal plasmid. 24 h after 
transfection the cells were lysed in 250 μL of lysis buffer (Promega, E194A) and 100 μL of 
samples were added to 750 μL of assay buffer (60 mM Na2HPO4 40 mM NaH2PO4 10 mM KCl, 1 
mM MgSO4, 50 mM β-mercaptoethanol, pH 7.0), in presence of 4 mg/mL of β-galactosidase 
substrate o-nitrophenyl-β-D-galactopyraniside (ONPG; Sigma-Aldrich, N1127) and incubated at 
37°C until yellow color appearance. Then, 500 μL of 1M Na2CO3 were added and 200 μL of the 
 36
final solution were transferred into a 96-well plate and 420-nm absorbance was evaluated using 
Enspire plate spectrofluorimeter (PerkinElmer). 
 
Statistical analysis  
In all figures, data are presented as mean ± SD. Statistical analysis has been performed by using the 
one-tailed unpaired Student t test to compare data between 2 groups, One-Way ANOVA to compare 
more than 2 groups of data, and Two-Way ANOVA to compare the effect of 2 different 
independent variables (see figure legends for details). When ANOVA resulted to be significant, we 
performed an Uncorrected Fisher LSD post hoc test (and the one-tailed unpaired Student t test when 
the variances between groups were highly different) (see figure legends for details) for multiple 
comparisons. Computations were done with the PRISM (ver. 6.0h) software (GraphPad Software, 
La Jolla, CA, USA). 
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ABBREVIATIONS 
3MA   3-methyladenine 
ALS   amyotrophic lateral sclerosis  
AR   androgen receptor 
BAG1   BCL2-associated athanogene 1 
BAG3   BCL2-associated athanogene 3 
C9ORF72  chromosome 9 open reading frame 72 
CMA   chaperone-mediated autophagy 
DYNC1H1  dynein cytoplasmic 1 heavy chain 1 
EHNA   erythro-9-[3-2-(hydrosynony)] adenine 
FA   formic acid 
FALS   familial ALS  
FRA   filter-retardation assay 
GAPDH  glyceraldheyde-3-phosphate dehydrogenase 
GP   dipeptide (glycine-proline) 
HDAC6  histone deacetylase 6 
HSP   heat shock protein 
HSPA   heat shock protein A 
HSPA1A heat shock protein 1A 
HSPA8/HSC70 heat shock protein 8 
HSPB8  small heat shock protein 8 
IF   immunofluorescence analysis 
IPSCS   induced pluripotent stem cells 
MAP1LC3/LC3 microtuble-associated protein 1 light chain 3 
MNDS  motoneuron diseases 
MNX1/HB9  motor neuron and pancreas homeobox 1 
 38
MTOC  microtubule-organization centre  
ND   neurodegenerative disease  
PQC   protein quality control  
SALS   sporadic ALS  
SBMA   spinal bulbar muscular atrophy  
SOD1   superoxide dismutase 1, soluble 
SQSTM1/p62  sequestosome 1 
STUB1/CHIP  stip1 homology and u-box containing protein 1 
T   testosterone 
TARDBP/TDP-43 tar dna binding protein 
TFEB   transcription factor eB 
TUBA/α-TUBULIN tubulin, alpha 
TUBB3/βIII-TUBULIN tubulin, beta 3 class III 
UPS   ubiquitin-proteasome systEM 
WB   western blot 
WT   wild type 
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Legends to figures 
Figure 1. Autophagic clearance of ARpolyQ. NSC34 cells cotransfected with AR.Q46 and 
pCDNA3 or HSPB8, and treated with vehicle (ethanol, EtOH) or 10 nM T, for 48 h. (A) 
Immunofluorescence microscopy (IF) analysis (63x magnification) of AR (green); nuclei were 
stained with DAPI (blue); scale bar: 20 μm. (B) WB and FRA show AR.Q46 total levels and 
AR.Q46 insoluble fraction respectively. TUBA was used as loading control. Bar graph represents 
the FRA mean relative optical density computed over 3 independent biological samples for each 
condition (n=3) ± SD (*=P<0.05, ***=P<0.001; Two-Way ANOVA followed by the Uncorrected 
Fisher LSD test). (C) Phase contrast imaging and IF performed on NSC34 cells transfected with 
Dync1h1 siRNA show cell morphology and dynein distribution. Scale bar: 20 μm. (D) WB analysis 
of NSC34 cells transfected with Dync1h1 siRNA shows the levels of dynein heavy chain; TUBA 
was used as loading control. Bar graph represents the WB mean relative optical density measured 
over 3 independent biological samples for each condition (n=3) ± SD (**=P<0.01, one-tailed 
unpaired Student t test). (E) FRA and WB of NSC34 stably expressing GFP-AR.Q39 and 
transfected with Dync1h1 siRNA show AR.Q39 insoluble fraction accumulation after 10 nM T 
treatment and reduction after dynein silencing. Bar graph represents the FRA mean relative optical 
density computed over 3 independent biological samples for each condition (n=3) ± SD (*=P<0.05, 
**=P<0.01; Two-Way ANOVA followed by the Uncorrected Fisher LSD test). 
 
Figure 2. Effect of dynein-silencing on autophagy and ARpolyQ clearance. (A) Confocal 
microscopy analysis (40x magnification) performed on NSC34 cells transfected with Dync1h1 
siRNA shows SQSTM1 or LC3 distribution (green); nuclei were stained with DAPI (blue); scale 
bars: 50 μm. Bar graphs represent the quantification of total green-fluorescence integrated density 
(IntDen) normalized on cells number. Six images were analyzed for each condition. (B) WB of 
LC3-I and LC3-II levels performed on NSC34 transfected with Dync1h1 siRNA and treated with 20 
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mM NH4Cl for the last 1.5 h. Nontargeting siRNA was used as control; TUBA was used as loading 
control. Bar graph represents the mean relative optical density computed over 3 independent 
biological samples for each condition (n=3) ± SD (*=P<0.05, **=P<0.01; Two-Way ANOVA 
followed by the Uncorrected Fisher LSD test); (C) WB of LC3-I and LC3-II levels performed on 
NSC34 treated with 100 μM EHNA and/or 20 mM NH4Cl for the last 1.5 h. Nontargeting siRNA 
was used as control; TUBA was used as loading control. Bar graphs represent the mean relative 
optical density computed over 3 independent biological samples for each condition (n=3) ± SD 
(*=P<0.05, **=P<0.01; Two-Way ANOVA followed by the Uncorrected Fisher LSD test). 
 
Figure 3. Autophagy modulation by EHNA treatment. NSC34 cells treated with DMSO, 100 μM 
EHNA and/or 100 mM trehalose for 48 h; (A, B) the bar graph represents Sqstm1 and Lc3 mRNA 
relative levels normalized with Rplp0 mRNA levels. Analysis was conducted on 4 independent 
biological samples for each condition (n=4) ± SD (**=P<0.01, ***=P<0.001; Two-Way ANOVA 
followed by the Uncorrected Fisher LSD test). (C) Confocal microscopy analysis shows SQSTM1 
and LC3 localization (40x magnification); scale bars: 50 μm. Bar graph represents the 
quantification of total green fluorescence integrated density (IntDen) normalized on cells number. 
Six images were analyzed for each condition (n=6) ± SD (**=P<0.01, **=P<0.001; one-tailed 
unpaired Student t test). Lower gain was used to acquire trehalose-treated cells (low sensitivity 
[L.S.]) compared to control (high sensitivity [H.S.]). (D) WB analysis shows SQSTM1 and LC3 
levels; TUBA was used as loading control. Bar graphs represent the mean relative optical density 
computed over 3 independent biological samples for each condition (n=3) ± SD of SQSTM1:TUBA 
(middle inset) and LC3-II:TUBA (low inset) ratio (*=P<0.05, **=P<0.01, ***=P<0.001; One-Way 
ANOVA followed by the Uncorrected Fisher LSD test).  
 
Figure 4. Effect of dynein ATPase activity-inhibition on ARpolyQ clearance. FRA and WB show 
ARpolyQ total levels and ARpolyQ insoluble fraction, respectively, of: (A) PC12 cells stably 
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transfected with AR.Q10 and AR.Q112 induced with 1 μg/mL doxycycline for 72 h. Cells were 
treated with ethanol (EtOH) or 10 nM T and/or EHNA 100 μM for the last 48 h prior to analysis. 
TUBA was used as loading control and bar graphs represent the FRA mean relative optical density 
computed over 3 independent biological samples for each condition (n=3) ± SD (***=P<0.001; 
One-Way ANOVA followed by the Uncorrected Fisher LSD test); (B) TR4 NSC34 cells stably 
transfected with GFP-AR.Q0 induced with 1 μg/mL doxycycline for 72 h; (C) TR4 NSC34 cells 
stably transfected with GFP-AR.Q39 induced with 1 μg/mL doxycycline for 72 h; (D) NSC34 cells 
transiently transfected with AR.Q46 for 48 h. Cells were treated with ethanol (EtOH) or 10 nM T 
and/or EHNA 100 μM for the last 48 h prior to analysis. (C and D) TUBA was used as loading 
control and bar graphs represent the FRA mean relative optical density computed over 3 
independent biological samples for each condition (n=3) ± SD (*=P<0.05, **=P<0.01; Two-Way 
ANOVA followed by the Uncorrected Fisher LSD test). (E) IF performed on NSC34 cells 
transfected with AR.Q46 and treated with 10 nM T or EtOH and 100 μM EHNA or DMSO for 48 h. 
AR was stained with AR H280 antibody (green), nuclei were stained with DAPI (blue) (63x 
magnification); scale bar: 20 μm. (F) Bar graph represents the mean percentage of transfected cells 
with inclusions computed over 3 independent biological samples for each condition (n=3) ± SD 
(*=P<0.05, ***=P<0.001; Two-Way ANOVA followed by the Uncorrected Fisher LSD test). Ten 
fields for each biological sample were analyzed. (G) WB analysis of PBS, Triton X100, SDS and 
FA lysates fractions of NSC34 cells transfected with AR.Q46 and treated with 10 nM T or EtOH 
and 100 μM EHNA or DMSO for 48 h. GAPDH was used as loading control.  
 
Figure 5. Dynein ATPase activity inhibition promotes ARpolyQ clearance via UPS. (A) NSC34 
cells stably transfected with GFP-AR.Q39, treated with 10 nM T, 10 mM 3MA and/or 100 μM 
EHNA for the last 48 h and/or 10 μM MG132 for the last 16 h. WB shows ARpolyQ levels and 
FRA shows ARpolyQ insoluble fraction. Bar graph represents the FRA mean relative optical 
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density computed over 3 independent biological samples for each condition (n=3) ± SD 
(**=P<0.01; ***=P<0.001; one-tailed unpaired Student t test). (B) NSC34 cells transfected with 
GFPu reporter and/or ARpolyQ and treated with 10 nM T and/or 100 μM EHNA. WB shows 
ARpolyQ and GFPu bands; TUBA was used as loading control. Bar graph represents the GFP WB 
densitometric analysis of 3 independent samples for each condition (n=3) ± SD (*=P<0.05; 
***=P<0.001; Two-Way ANOVA followed by the Uncorrected Fisher LSD test); (C) Proteasome 
chymotryptic activity assay performed on NSC34 treated with DMSO or 100 μM EHNA and 10 
μM MG132 used as negative control. Bar graph represents the mean relative fluorescence 
normalized on control group and computed over 4 independent biological samples for each 
condition (n=4) ± SD (***=P<0.001, One-Way ANOVA followed by the Uncorrected Fisher LSD 
test). (D) Proteasome chymotryptic activity assay performed on NSC34 transfected with AR.Q46 
and treated with 10 nM T, DMSO or 100 μM EHNA and 10 μM MG132 used as negative control. 
Bar graph represents the mean relative fluorescence normalized on control group and computed 
over 4 independent biological samples for each condition (n=4) ± SD (***=P<0.001, One-Way 
ANOVA followed by the Uncorrected Fisher LSD test). (E) β-galactosidase assay performed on 
NSC34 cells transfected with pCMV-β and treated with DMSO or 100 μM EHNA for 24 or 48 h 
after transfection. Bar graph represents the mean relative absorbance normalized on transfected 
cells treated for 48 h and computed over 6 independent biological samples for each condition (n=6) 
± SD (Two-Way ANOVA, not significant). (F) MTT assay performed on NSC34 cells treated with 
DMSO or 100 μM EHNA for 24 or 48 h. Bar graph represents the mean relative absorbance 
normalized on untreated group and computed over 6 independent biological samples for each 
condition (n=6) ± SD (One-Way ANOVA, not significant).  
 
Figure 6. BAG1 upregulation reduces ARpolyQ accumulation. (A to C) NSC34 cells treated with 
DMSO or 100 μM EHNA for 48 h. The bar graphs represent Hspb8 (A), Bag3 (B) and Bag1 (C) 
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mRNA levels normalized with Rplp0 mRNA levels. Four independent biological samples for each 
condition were analyzed (n=4) ± SD (***=P<0.001; One-Way ANOVA followed by the 
Uncorrected Fisher LSD test). (D) NSC34 cells overexpressing AR.Q46 alone or coexpressing 
BAG1 and treated with T for last 48 h. FRA shows insoluble AR-polyQ levels (upper panel) and 
bar graph represents the FRA mean relative optical density computed over 3 independent biological 
samples for each condition (n=3) ± SD (*=P<0.05, ***=P<0.001; Two-Way ANOVA followed by 
the Uncorrected Fisher LSD test). WB (lower panel) shows AR.Q46 and BAG1 protein levels. (E) 
NSC34 cells expressing AR.Q46 alone or coexpressing BAG1 and treated with 10 nM T for last 48 
h and/or 10 μM MG132 for last 16 h. FRA shows insoluble AR-polyQ levels, bar graph represents 
the FRA mean relative optical density computed over 3 independent biological samples for each 
condition (n=3) ± SD (*=P<0.05, ***=P<0.001; Two-Way ANOVA followed by the Uncorrected 
Fisher LSD test and one-tailed unpaired Student t test for control condition). (F) WB analysis of 
NSC34 cells transfected with Bag1 siRNA shows the levels of BAG1; TUBA was used as loading 
control. Bar graph represents the WB mean relative optical density computed over 3 independent 
biological samples for each condition (n=3) ± SD (**=P<0.01, one-tailed unpaired Student t test). 
(G) FRA and WB of NSC34 transfected with AR.Q46 and with Bag1 siRNA shows AR.Q46 
insoluble fraction; TUBA was used as loading control. Bar graph represents the FRA densitometric 
analysis of 3 independent biological samples for each condition (n=3) ± SD (**=P<0.01; 
***=P<0.001; one-tailed unpaired Student t test). 
 
Figure 7. EHNA effects on neuronal and motoneuronal cells obtained by differentiation of human 
iPSCs generated from SBMA patients. (A) IF analysis of neuronal and motoneuronal cells obtained 
by differentiation of human iPSCs generated from SBMA patients and treated with ethanol or 10 
nM T (40x magnification). TUBB3 (green) and SMI312 (red) (upper inset), AR (green) and 
MNX1/HB9 (red) (lower inset). Nuclei were stained with DAPI (blue); scale bars: 30 μm. (B) Bar 
graph represents the percentage of MNX1/HB9-positive cells; 6 fields for each condition were 
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analyzed (n=6) ± SD (one-tailed unpaired Student t test, not significant). (C to I) RealTime PCR 
analyses performed on iPSCs differentiated to neuronal cells treated with 10 nM T and/or 100 μM 
EHNA for last 48 h. The bar graphs represent HSPB8 (C), BAG3 (D), BAG1 (E), SQSTM1 (F), LC3 
(G), TFEB (H) and BECN1 (I) mRNA levels normalized with RPLP0 mRNA levels. Four 
independent samples for each condition were analyzed (n=4) ± SD (*=P<0.05, **=P<0.01, 
***=P<0.001; Two-Way ANOVA followed by the Uncorrected Fisher LSD test). 
 
Figure 8. Effects of dynein inhibition on SOD1 and TARDBP insoluble species. (A) NSC34 cells 
expressing wtSOD1 and SOD1G93A treated with DMSO or 100 μM EHNA for last 48 h. FRA shows 
SOD1G93A accumulation compared to wtSOD1 and SOD1G93A reduction after 100 μM EHNA 
treatment. WB shows total level of transfected SOD1, TUBA was used as loading control. (B) 
NSC34 stably transfected with wtSOD1 or SOD1G93A induced with doxycycline and treated with 
DMSO or 100 μM EHNA for last 48 h. FRA shows SOD1G93A accumulation compared to wtSOD1 
and SOD1G93A reduction after 100 μM EHNA treatment. WB shows total level of transfected SOD1, 
TUBA was used as loading control. (C) NSC34 expressing FL and TARDBP∆C treated with DMSO 
or 100 μM EHNA for last 48 h. FRA shows TARDBP∆C accumulation compared to FL TARDBP 
and TARDBP∆C reduction after 100 μM EHNA treatment. WB shows total level of transfected 
TARDBP, TUBA was used as loading control; (A to C) Bar graphs represent the FRA mean 
relative optical density computed over 3 independent biological samples for each condition (n=3) ± 
SD (**=P<0.01, ***=P<0.001; Two-Way ANOVA followed by the Uncorrected Fisher LSD test). 
(D and E) NSC34 expressing SOD1G93A (D) or TARDBP∆C (E) and treated with DMSO, 100 μM 
EHNA and/or 10 mM 3MA for the last 48 h and 10 μM MG132 for the last 16 h. FRAs show 
SOD1G93A (D) or TARDBP∆C (E) accumulation after 3MA and MG132 treatments. EHNA 
treatment counteracts 3MA activity but not MG132 activity. WBs show total level of transfected 
SOD1 (D) or TARDBP∆C (E), TUBA or GAPDH was used as loading control. Bar graphs represent 
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the FRA mean relative optical density computed over 3 independent biological samples for each 
condition (n=3) ± SD (*=P<0.05, **=P<0.01, ***=P<0.001; Two-Way ANOVA followed by the 
Uncorrected Fisher LSD test and one-tailed unpaired Student t test for control conditions).  
 
Figure 9. Effects of dynein inhibition on poly-GP insoluble fraction. (A) NSC34 cells expressing 
poly-GP (100 repeats) treated with 10 mM 3MA and/or 100 μM EHNA for the last 48 h prior to 
analysis and/or 10 μM MG132 for the last 16 h prior to analysis. FRA shows poly-GP insoluble 
fraction. Bar graphs represent the FRA mean relative optical density computed over 3 independent 
biological samples for each condition (n=3) ± SD (**=P<0.01; ***=P<0.001; one-tailed unpaired 
Student t test); (B) the portion shown in A by the rectangle has been magnified to show the 
differences between short bars. WB shows total level of transfected poly-GP; TUBA was used as 
loading control. 
 
 
 
 
 
 









